First-in-human, phase I dose-escalation study of the pharmacokinetics and safety of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, dUTPase inhibitor (TAS-114) in healthy male volunteers

Trial Profile

First-in-human, phase I dose-escalation study of the pharmacokinetics and safety of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, dUTPase inhibitor (TAS-114) in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2016

At a glance

  • Drugs TAS 114 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 29 Oct 2013 New trial record
    • 21 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top